Company profile: Immunome
1.1 - Company Overview
Company description
- Provider of immunotherapy and antigen discovery solutions, developing targeted therapies including IM-4320 (IL-38-focused tumor control) and 177Lu-FAP radioligand for solid tumors aimed at enhanced tumor radiation delivery. Offers Memory B cell hybridoma technology, a Targeted Effector platform using small-molecule ligands for payload delivery and radioligand design, and the Immunome Discovery Engine to identify novel therapeutic targets and antibodies.
Products and services
- Immunome Discovery Engine: Research-grade system that isolates patient-derived B cells, employs hybridoma technology, and evaluates novel targets and antibodies for therapeutic potential
- Memory B cell hybridoma technology: High-throughput platform that rapidly screens and functionally characterizes novel antibodies and targets to advance therapeutic development
- Targeted Effector platform: Ligand-directed architecture utilizing small-molecule ligands with antibody-like specificity to deliver payloads to disease-implicated cells, including engineering radioligand therapies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Immunome
Viome Life Sciences
HQ: United States
Website
- Description: Provider of scientific discovery, research, and development services for health and chronic disease, offering RNA-based consumer analyses for health insights and precision nutrition, and advancing prediction, precision diagnostics, and therapeutics for chronic diseases, cancer, and aging, with RNA sequencing tests including gut microbiome, human gene expression, saliva, and vaginal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Viome Life Sciences company profile →
BioVie
HQ: United States
Website
- Description: Provider of biotechnological research and development focused on innovative therapies for the treatment of liver disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVie company profile →
Theriva Biologics
HQ: United States
Website
- Description: Provider of biologics for the prevention and treatment of serious infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theriva Biologics company profile →
Affini-T Therapeutics
HQ: United States
Website
- Description: Provider of autologous TCR-T cell therapies targeting oncogenic driver mutations in solid tumors and off-the-shelf bispecific T cell engagers. Offers the TAILOR discovery platform leveraging machine learning and high-throughput screening, TUNE to enhance persistence and functionality via synthetic biology, and THRIVE for optimized manufacturing and gene editing. Conducts clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affini-T Therapeutics company profile →
AVEO Oncology
HQ: United States
Website
- Description: Provider of targeted cancer therapeutics and oncology development platforms. Products include FOTIVDA (tivozanib), an oral VEGFR TKI approved for relapsed/refractory advanced RCC. Pipeline includes ficlatuzumab (anti-HGF) for HNSCC, AV-380 (anti-GDF15) for cancer cachexia, and AV-203, a HER3 inhibitory antibody. Offers an integrated cancer biology and Human Response platform for efficient discovery and development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AVEO Oncology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Immunome
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Immunome
2.2 - Growth funds investing in similar companies to Immunome
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Immunome
4.2 - Public trading comparable groups for Immunome
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →